In this article our expert Lynne Byers and Jenny Yu from Munich Re Group compare regulatory findings from the U.S. FDA and the EMA, specifically 483s and non-conformance reports. They provide insight into emerging trends from both agencies and highlight the important questions managers need to ask to stay in compliance.